Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Blanked the page)
Tag: Blanking
 
(49 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
<span id="BackToTop"></span>
+
 
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 
−
[[#top|Back to Top]]
 
−
</div>
 
−
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Renal_cell_carcinoma|main RCC page]] for current regimens.
 
−
{| class="wikitable" style="float:right; margin-right: 5px;"
 
−
|-
 
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
−
|}
 
−
{{TOC limit|limit=3}}
 
−
=Metastatic disease, first-line=
 
−
==Interferon alfa-2a & Interleukin-2 {{#subobject:77d26e|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:89bca8|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
! style="width: 20%" |Study
 
−
! style="width: 20%" |Years of enrollment
 
−
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
! style="width: 20%" |Comparator
 
−
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM199804303381805 Negrier et al. 1998]
 
−
|1992-1995
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|1. [[Renal_cell_carcinoma#High-dose_Interleukin-2|HD IL-2]]<br>2. [[Renal_cell_carcinoma#Interferon_alfa-2a_monotherapy|Interferon alfa-2a]]
 
−
| style="background-color:#1a9850" |Superior EFS
 
−
|-
 
−
|[https://doi.org/10.1007/s00262-009-0773-9 Passalacqua et al. 2009]
 
−
|1998-2003
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#Interferon_alfa-2a_.26_Interleukin-2|IFN & IL-2]]; maintenance
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
−
|-
 
−
|[https://doi.org/10.1158/1078-0432.ccr-08-0236 Négrier et al. 2008 (LEONB-PERCY-DUO)]
 
−
|2000-2005
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#Interferon_alfa-2a_.26_Interleukin-2|IFN & IL-2]]; IV IL-2
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Interferon alfa-2a (Roferon-A)]]
 
−
*[[Aldesleukin (Proleukin)]]
 
−
</div></div>
 
−
===References===
 
−
#Négrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T; Groupe Français d'Immunothérapie. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998 Apr 30;338(18):1272-8. [https://doi.org/10.1056/NEJM199804303381805 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9562581 PubMed]
 
−
#'''LEONB-PERCY-DUO:''' Négrier S, Perol D, Ravaud A, Bay JO, Oudard S, Chabaud S, Fargeot P, Delva R, Deplanque G, Gravis G, Escudier B; French Immunotherapy Group. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res. 2008 Sep 15;14(18):5907-12. [https://doi.org/10.1158/1078-0432.ccr-08-0236 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18794104/ PubMed] NCT00416871
 
−
#Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. Epub 2009 Sep 25. [https://doi.org/10.1007/s00262-009-0773-9 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19779715 PubMed]
 
−
==Interferon alfa-2b monotherapy {{#subobject:6b5be6|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:39f1ab|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa003013 Flanigan et al. 2001 (SWOG 8949)]
 
−
|1991-1998
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
|-
 
−
|[https://doi.org/10.1016/S0140-6736(01)06103-7 Mickisch et al. 2001 (EORTC 30947)]
 
−
|1995-1998
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#cbd5e8">
 
−
====Preceding treatment====
 
−
*[[Surgery#Renal_cell_carcinoma_surgery|Nephrectomy]] versus [[Surgery#No_surgery|no preceding treatment]]
 
−
</div>
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Interferon alfa-2b (Intron-A)]]
 
−
</div></div>
 
−
===References===
 
−
#'''EORTC 30947:''' Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; [[Study_Groups#EORTC|EORTC]] Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001 Sep 22;358(9286):966-70. [https://doi.org/10.1016/S0140-6736(01)06103-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11583750 PubMed]
 
−
#'''SWOG 8949:''' Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6;345(23):1655-9. [https://doi.org/10.1056/NEJMoa003013 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11759643 PubMed]
 
−
#'''ECOG E2898:''' NCT00005966
 
−
==Medroxyprogesterone monotherapy {{#subobject:6c7bb9|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:8b5e67|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1016/S0140-6736(98)03544-2 Ritchie et al. 1999 (MRC RE01)]
 
−
|1992-1997
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[Renal_cell_carcinoma#Interferon_alfa-2a_monotherapy|IFN alfa-2a]]
 
−
| style="background-color:#fc8d59" |Seems to have inferior OS
 
−
|-
 
−
|[https://doi.org/10.1002/cncr.23056 Negrier et al. 2007 (PERCY Quattro)]
 
−
|2000-2004
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|1. [[Renal_cell_carcinoma#Interferon_alfa-2a_monotherapy|IFN alfa-2a]]<br>2. [[#Interferon_alfa-2a_.26_Interleukin-2|IFN alfa-2a & IL-2]]<br>3. [[Renal_cell_carcinoma#Low-dose_Interleukin-2|IL-2]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
−
|-
 
−
|}
 
−
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Hormone replacement therapy====
 
−
*[[Medroxyprogesterone (MPA)]]
 
−
</div></div>
 
−
===References===
 
−
#'''MRC RE01:''' Ritchie A, Griffiths G, Parmar M; Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999 Jan 2;353(9146):14-7. [https://doi.org/10.1016/S0140-6736(98)03544-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10023944 PubMed]
 
−
#'''PERCY Quattro:''' Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B; French Immunotherapy Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007 Dec 1;110(11):2468-77. [https://doi.org/10.1002/cncr.23056 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17932908/ PubMed] NCT00416429
 
−
==Vinblastine monotherapy {{#subobject:8c9fac|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:5d6145|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.1999.17.9.2859 Pyrhönen et al. 1999]
 
−
|1988-1994
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#Vinblastine_.26_Interferon_alfa-2a_88|Vinblastine & IFN alfa-2a]]
 
−
| style="background-color:#d73027" |Inferior OS
 
−
|-
 
−
|}
 
−
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Vinblastine (Velban)]]
 
−
</div></div>
 
−
===References===
 
−
# Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999 Sep;17(9):2859-67. [https://doi.org/10.1200/JCO.1999.17.9.2859 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10561363 PubMed]
 
−
=Metastatic disease, second-line=
 
−
==FC, then allo HSCT {{#subobject:1a1ed9|Regimen=1}}==
 
−
FC: '''<u>F</u>'''ludarabine & '''<u>C</u>'''yclophosphamide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:9ce8f1|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
! style="width: 50%" |Study
 
−
! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM200009143431101 Childs et al. 2000]
 
−
| style="background-color:#ffffbe" |Non-randomized, <20 pts
 
−
|-
 
−
|}
 
−
{{#lst:Allogeneic HSCT|9ce8f1}}
 
−
</div></div>
 
−
===References===
 
−
#Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Clave E, Epperson D, Mayo V, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-8. [https://doi.org/10.1056/NEJM200009143431101 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10984562 PubMed]
 
−
==Interferon alfa-2a monotherapy {{#subobject:8f04d6|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:b28245|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2005.07.114 Aass et al. 2005 (EORTC 30951)]
 
−
|1998-2001
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[#Interferon_alfa-2a_.26_Isotretinoin|IFN alfa-2a & Isotretinoin]]
 
−
| style="background-color:#fc8d59" |Seems to have inferior OS
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Interferon alfa-2a (Roferon-A)]]
 
−
</div></div>
 
−
===References===
 
−
# '''EORTC 30951:''' Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8. [https://doi.org/10.1200/JCO.2005.07.114 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15961764 PubMed] NCT00002737
 
−
==Interferon alfa-2a & Isotretinoin {{#subobject:8f038c|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:b52145|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2005.07.114 Aass et al. 2005 (EORTC 30951)]
 
−
|1998-2001
 
−
|style="background-color:#1a9851"|Phase 3 (E-esc)
 
−
|[[#Interferon_alfa-2a_monotherapy|IFN alfa-2a]]
 
−
| style="background-color:#91cf60" |Seems to have superior OS
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Interferon alfa-2a (Roferon-A)]]
 
−
*[[Isotretinoin (Accutane)]]
 
−
</div></div>
 
−
===References===
 
−
# '''EORTC 30951:''' Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8. [https://doi.org/10.1200/JCO.2005.07.114 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15961764 PubMed] NCT00002737
 
−
==Interferon alfa-2c monotherapy {{#subobject:31b4d6|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:0f1524|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033601/ De Mulder et al. 1995 (EORTC 30885)]
 
−
|1988-1990
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[#Interferon_alfa-2c_.26_Interferon_gamma_99|IFN alfa-2c & IFN gamma]]
 
−
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Interferon alfa-2c (Berofor)]]
 
−
</div></div>
 
−
===References===
 
−
# '''EORTC 30885:''' De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R; EORTC Genitourinary Group. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. Br J Cancer. 1995 Feb;71(2):371-5. [https://www.nature.com/articles/bjc199575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033601/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/7841054 PubMed]
 
−
==Megestrol monotherapy {{#subobject:4b50ea|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:52dc53|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2007.14.5029 Ravaud et al. 2008]
 
−
|2002-2005
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[#Lapatinib_monotherapy_99|Lapatinib]]
 
−
|style="background-color:#ffffbf"|Did not meet primary endpoint of TTP
 
−
|-
 
−
|}
 
−
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Hormone replacement therapy====
 
−
*[[Megestrol (Megace)]]
 
−
</div></div>
 
−
===References===
 
−
# Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol. 2008 May 10;26(14):2285-91. [https://doi.org/10.1200/JCO.2007.14.5029 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18467719 PubMed]
 
−
[[Category:Renal cell carcinoma regimens]]
 
−
[[Category:Historical regimens]]
 
−
[[Category:Disease-specific pages]]
 
−
[[Category:Genitourinary cancers]]
 

Latest revision as of 00:13, 18 June 2023

Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=73776"